---
url: https://www.servicesaustralia.gov.au/systemic-light-chain-amyloidosis
title: Systemic light chain amyloidosis - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:53.340Z
source: servicesaustralia.gov.au
---
# Systemic light chain amyloidosis

The PBS subsidises daratumumab for patients with newly diagnosed systemic light chain amyloidosis.

## on this page

-   [Patient eligibility](#a1)
-   [Treatment specifics](#a2)
-   [Authority applications](#a3)
-   [More information](#a4)

Please note: Youâ€™ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with daratumumab under the _National Health Act 1953_, section 85 for patients with newly diagnosed systemic light chain amyloidosis.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home) on the PBS website outlines the restrictions for prescribing daratumumab.

## Treatment specifics

To be eligible for PBS-subsidised treatment with daratumumab, patients must be treated by a haematologist (this does not exclude treatment via a multidisciplinary team, but the PBS authority application must be written by the treating haematologist).

## Authority applications

### Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised daratumumab to treat newly diagnosed systemic light chain amyloidosis can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS authority approvals](/health-professionals-contact-information?context=20#pbsauthority).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [systemic light chain amyloidosis newly diagnosed - daratumumab - initial authority application form](/pb341?context=20)
-   relevant attachments.

### Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsided daratumumab to treat newly diagnosed systemic light chain amyloidosis can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS authority approvals](/health-professionals-contact-information?context=20#pbsauthority) line.

## More information

Call the [PBS authority approvals line](/health-professionals-contact-information?context=60090#pbsauthority) for more information.
